Dossier assessment
Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V
Report documents
-
Extract of dossier assessment
Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V
-
Dossier assessment
Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V
Dossier assessment
Adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after ≥ 2 lines of systemic therapy
- Patients who are eligible for high-dose therapy: added benefit not proven
- Patients who are not eligible for high-dose therapy: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-11-16 A G-BA decision was published.
Project details
- Project no.
- A23-45
- Commission
- Commission awarded on 15.05.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45
Status: Commission completed